Breast Cancer Follow-Up After Treatment: Mammograms, Tests, Follow-Up Schedule and Recurrence Monitoring in India

Completing breast cancer treatment is an important milestone, but regular follow-up remains essential. Follow-up appointments help doctors monitor recovery, detect possible recurrence, manage long-term side effects and check the health of the remaining breast tissue. This guide explains the recommended follow-up schedule, mammograms, other investigations, warning signs and survivorship care for patients planning breast cancer treatment in India.

Related reading: recurrence, metastatic / Stage 4 disease, surgery, lumpectomy vs mastectomy, radiation, chemotherapy, hormone therapy, lymphoedema and cost.

Completing breast cancer treatment can bring relief, but it does not mean that medical care is over. Patients who have undergone surgery, chemotherapy, radiation therapy or other treatments usually need regular follow-up with their cancer care team.

Follow-up serves several purposes:

The purpose is not to perform every possible test at every visit. It is to use appropriate examinations and investigations based on the patient's original diagnosis, treatment history, current symptoms and risk factors.

A follow-up appointment is generally more than a discussion about whether cancer has returned. The doctor reviews the patient's health, asks about new symptoms, examines the relevant areas and checks for treatment-related complications.

A typical appointment may include:

Some consultations can be conducted virtually when an in-person examination or investigation is not required. However, new symptoms or abnormal findings may require a physical visit.

There is no single schedule suitable for every patient. Follow-up depends on the original cancer stage, tumour biology, surgery, radiation treatment, ongoing medicines and risk of recurrence.

A commonly used follow-up pattern after treatment for early-stage breast cancer is:

This is a general framework, not a fixed rule. Patients with locally advanced disease, residual cancer after preoperative chemotherapy, complex treatment histories or new symptoms may need closer monitoring. Risk-based approaches (including recent ASCO guidance) support individualised surveillance rather than identical testing for every survivor.

Ask the treating oncologist for a written schedule explaining when consultations, mammograms and any other investigations are due. Broader staging context: breast cancer stages.

Breast cancer screening generally refers to tests performed in people who do not have a known breast cancer diagnosis, with the aim of detecting cancer early.

Breast cancer follow-up refers to medical care after a patient has already been diagnosed and treated for breast cancer. Follow-up may include mammography, physical examination and assessment of treatment-related effects.

A patient who has undergone breast cancer treatment should follow a surveillance plan designed for their medical history rather than relying only on the general population screening schedule.

Mammography is one of the most important investigations used to monitor breast tissue after treatment. It uses low-dose X-rays to create images of the breast and can help identify suspicious changes before they become noticeable during a physical examination. The need for mammography depends mainly on the type of surgery performed — see surgery in India and lumpectomy vs mastectomy.

A lumpectomy removes the tumour while preserving most of the breast. Because breast tissue remains, mammography is generally recommended after treatment.

The first surveillance mammogram is commonly performed around 6–12 months after completing radiation therapy, depending on the clinical situation and local protocol. After that, regular mammography is recommended.

Risk-based patterns discussed in recent ASCO guidance include annual mammography during early years after breast-conserving surgery, with selected lower-risk patients aged 50 or older possibly extending intervals after remaining recurrence-free, while younger patients and those with triple-negative or HER2-positive disease often continue annual surveillance. These recommendations should not be applied automatically — the treating team decides.

A mastectomy removes most or all of the breast tissue on the operated side. Routine mammography is generally not performed on the side where the entire breast has been removed.

Some patients undergo breast reconstruction after mastectomy using implants or their own tissue. Routine screening mammography is generally not performed on a reconstructed breast after mastectomy. New lumps, skin changes or persistent discomfort should still be assessed — often with ultrasound, MRI or another test.

Some patients experience discomfort during mammography, particularly if the treated breast is sensitive or has scar tissue. Tell the radiographer about previous surgery, radiation, reconstruction or tenderness before the examination so positioning can be adjusted.

Mammography is important, but it is not the only part of follow-up. Other tests may be needed when a patient has specific symptoms, abnormal examination findings, ongoing treatment requirements or a risk of long-term complications.

Breast ultrasound uses sound waves to examine breast tissue and nearby structures. It may be recommended for a new lump, an unclear mammogram finding, a lump near a surgical scar, an enlarged lymph node or further assessment of a specific finding. It is not generally a replacement for routine mammography when mammography is indicated.

MRI may be considered for selected high inherited or familial risk, certain younger patients with dense tissue and additional risk factors, unclear findings on mammography or ultrasound, evaluation of a suspected recurrence, or selected complex reconstruction cases. MRI is not routinely required for every breast cancer survivor.

CT, PET-CT, bone scan and brain MRI may be recommended when symptoms or examination findings raise concern about spread or another medical problem — for example persistent unexplained bone pain, neurological symptoms, or suspected distant disease (see metastatic breast cancer).

Routine CT of the chest, abdomen and pelvis, annual PET-CT, routine bone scans or routine brain MRI are generally not recommended solely to search for distant recurrence in asymptomatic patients after early-stage treatment.

Patients often expect regular blood tests after completing treatment. The need depends on the treatment received, ongoing medicines, symptoms and other health conditions.

A normal tumour marker does not guarantee that cancer has not returned. An elevated result does not automatically mean recurrence. Doctors interpret results with symptoms, examination and imaging.

More tests do not always mean better monitoring. Unnecessary investigations can cause anxiety, false alarms, additional procedures and avoidable expense.

For most patients treated for early-stage breast cancer who have no symptoms or concerning examination findings, routine surveillance generally focuses on medical history, physical examination and mammography of remaining breast tissue when indicated.

These tests can still be important when symptoms, examination findings or a specific clinical concern justify them. The aim is appropriate testing, not simply more testing. See also recurrence warning signs.

Chemotherapy can affect several parts of the body. Some side effects improve within weeks or months, while others may last longer. Follow-up after chemotherapy may include assessment of persistent fatigue, neuropathy, memory or concentration changes, menstrual and fertility concerns, heart function after certain medicines, bone health, blood counts when indicated and emotional well-being.

Certain chemotherapy medicines, particularly anthracyclines, and some HER2-targeted treatments can affect heart function. Depending on medicines, cumulative doses and risk factors, doctors may recommend an echocardiogram or other cardiac assessment. Report new breathlessness, leg swelling, chest discomfort, unusual fatigue or palpitations.

Some chemotherapy medicines can damage peripheral nerves — tingling, numbness, burning, difficulty with fine tasks or balance problems. Persistent symptoms should be discussed because they may affect daily activities and safety.

Chemotherapy may affect ovarian function and fertility. Younger patients who wish to have children should discuss concerns with their oncologist and, where appropriate, a fertility specialist.

After radiation, doctors may assess skin changes, breast swelling or firmness, pain or tenderness, changes in breast shape, shoulder stiffness, lung-related symptoms after chest radiation and rare long-term heart effects depending on the treated side and technique.

Report persistent cough, worsening breathlessness, chest pain or new swelling rather than assuming these are always normal consequences of radiation.

Many patients with hormone receptor-positive breast cancer take hormone therapy for several years — tamoxifen, letrozole, anastrozole, exemestane or ovarian suppression medicines. Follow-up is important because these medicines can have long-term effects. See also hormone therapy side effects.

Doctors may review menstrual or menopausal symptoms, unusual vaginal bleeding, blood-clot symptoms and medicine tolerance. Unusual vaginal bleeding should be assessed promptly. Seek urgent care for sudden leg swelling or pain, chest pain or unexplained breathlessness.

Aromatase inhibitors can cause joint pain, muscle discomfort, hot flushes, vaginal dryness and loss of bone density. Bone mineral density testing and bone-protection measures may be recommended.

Not necessarily. Some patients may continue beyond five years depending on stage, lymph-node involvement, recurrence risk, side effects and overall health. Do not stop prescribed hormone therapy without discussing risks and alternatives with the oncologist.

Aromatase inhibitors, ovarian suppression and chemotherapy-induced menopause can affect bone density. Doctors may recommend DEXA bone mineral density testing, adequate calcium intake, vitamin D assessment, weight-bearing and resistance exercise, and medicines to protect bone health in selected patients.

A DEXA scan is different from a bone scan used to investigate suspected cancer spread.

Lymphoedema is swelling from lymphatic fluid build-up, commonly affecting the arm after certain lymph-node surgery or radiation. Symptoms include arm or hand swelling, heaviness, skin tightness, reduced flexibility, discomfort and difficulty with jewellery or clothing on the affected side. Read the dedicated lymphoedema guide.

Lymphoedema can develop months or years after treatment. Management may include specialist assessment, compression garments, exercise programmes, manual lymphatic drainage in selected patients, skin care and infection-prevention education. Sudden redness, warmth, pain and fever in a swollen arm may indicate infection and need prompt assessment.

Not every symptom indicates recurrence. Many are caused by treatment effects, ageing or unrelated conditions. Persistent or unexplained changes should still be discussed.

These emergency symptoms should not wait for the next routine appointment. Distant-disease context: Stage 4 breast cancer.

No. This is one of the most common misconceptions about breast cancer follow-up. PET-CT can be useful when doctors need to investigate suspected recurrence or assess disease in selected situations, but routine annual PET-CT is not generally recommended for asymptomatic early-stage survivors.

Follow-up aims to identify new breast cancers, local recurrence and clinically significant symptoms. Mammography can help detect suspicious changes in remaining breast tissue. Clinical examination may identify new lumps, skin changes or enlarged lymph nodes.

No follow-up programme can guarantee that every recurrence will be detected before symptoms develop. Patients should seek advice for new changes rather than waiting for the next scheduled scan. More detail: breast cancer recurrence.

A survivorship care plan is a written document that explains what happens after the main course of cancer treatment. It helps the patient, oncologist and other clinicians understand the treatment history and future care requirements.

Keep a copy and share it with doctors involved in ongoing care — especially when travelling between countries.

Many patients return to work, family responsibilities, travel and everyday activities after completing treatment. Recovery differs: some regain previous activity within months; others experience longer-lasting fatigue, pain, arm stiffness, lymphoedema or emotional distress.

Regular physical activity can support recovery. Depending on condition, activities may include walking, gentle stretching, yoga, strength training, cycling or swimming. Patients with recent surgery or bone metastases should seek medical advice before starting a new programme.

There is no single diet that prevents recurrence. A balanced diet can support a healthy weight and recovery. Discuss supplements and herbal products with doctors — some can interfere with medicines.

Fear of recurrence is common. Support may include counselling, psycho-oncology services, support groups, family support and help from survivorship or palliative care teams when appropriate.

India has hospitals and cancer centres that provide breast cancer treatment and follow-up. Continuity of care matters whether treatment was completed in India or abroad.

Specialists in Delhi NCR, Mumbai, and national filters for medical, surgical and radiation oncology can support follow-up and second opinions.

There is no single price for breast cancer follow-up. Costs depend on consultation frequency, mammography, selected blood tests, management of side effects and whether new symptoms require restaging. Related treatment pathway ranges used for planning:

See the broader breast cancer treatment cost guide. GAF Healthcare can help request a case-specific follow-up estimate — we do not invent fixed package prices for every survivor.

For patients travelling from Tanzania, Kenya, Uganda, Ethiopia, Zambia, Cameroon, Iraq, Oman, Saudi Arabia and other countries, follow-up planning should begin before returning home.

A local doctor can help with routine care; suspected recurrence or complex complications may still need specialist oncology review. Pathway: international patients.

GAF Healthcare assists international patients exploring treatment and medical coordination in India. For breast cancer survivors, support may include arranging follow-up consultations, coordinating review of pathology and treatment records, assisting with recommended mammography and investigations, helping patients understand their follow-up schedule, coordinating opinions for new symptoms and supporting hospital and travel arrangements.

The treating oncologist remains responsible for deciding which tests are necessary and interpreting results. Patients with emergency symptoms should seek immediate local medical attention rather than waiting to arrange travel.

A commonly used schedule is every 3–6 months during the first few years, every 6–12 months during years four and five, and annually thereafter. Your doctor may recommend a different schedule based on your risk and treatment history.

After breast-conserving surgery and radiation, the first surveillance mammogram is commonly performed around 6–12 months after radiation is completed. Your treating team will confirm the appropriate date.

Routine mammography is generally not performed on the side where the breast has been completely removed. If the opposite breast remains, it generally continues to require surveillance mammography.

No. Routine annual PET-CT is not generally recommended for asymptomatic patients treated for early-stage breast cancer. It may be used when symptoms or clinical findings justify further investigation.

Not for everyone. Blood tests are selected according to symptoms, ongoing medicines, treatment-related risks and other medical conditions.

CA 15-3 is not generally recommended as a routine recurrence-screening test for asymptomatic patients after early-stage breast cancer treatment. It may have a role in selected patients with advanced disease.

Yes. Mammography is useful but cannot detect every recurrence. A recurrence may develop in the chest wall, lymph nodes or distant organs. New or persistent symptoms should be assessed even if the latest mammogram was normal.

Not everyone needs breast MRI. It may be recommended for selected high-risk patients or when mammography and ultrasound do not adequately explain a clinical finding.

Follow-up generally continues for many years. Some hormone receptor-positive cancers can recur long after the original treatment, so long-term care remains important.

If hormone therapy has been prescribed, continue it for the recommended duration unless your oncologist advises otherwise. Do not stop it independently because of side effects; discuss alternatives with your doctor.

Many patients can travel after treatment, but the timing depends on recovery, current medicines, infection risk, blood counts, mobility and other medical factors. Ask the treating team before making travel plans.

Contact your treating doctor for an examination. A new lump does not always mean cancer has returned, but it should not be ignored.

Many patients can exercise safely and benefit from regular physical activity. The programme should be adjusted for surgical recovery, lymphoedema, heart health and bone involvement.

Yes. Some important changes may not cause symptoms initially. Regular consultations and recommended mammography remain important even when you feel well.

Some follow-up consultations can be conducted virtually, particularly when reviewing symptoms, reports or ongoing medicines. A physical examination or imaging may still be necessary depending on the situation.

Completing breast cancer treatment is a major milestone, but follow-up remains an important part of long-term care. A good plan includes regular consultations, appropriate mammography, monitoring of treatment-related side effects and attention to new symptoms.

More tests do not automatically mean better care. For most patients who have completed treatment for early-stage breast cancer and have no symptoms, routine care generally focuses on clinical assessment and mammography rather than repeated PET-CT scans, CT scans or tumour-marker testing.

Leave the treating hospital with a clear written survivorship plan — when to return, which investigations are required, which medicines to continue and what symptoms need medical attention.

Medical disclaimer: This article is for general educational purposes and does not replace individual medical advice. Follow-up schedules and investigations should be personalised by the treating oncology team. Patients with new or worsening symptoms should seek medical assessment rather than waiting for their next routine appointment.